Business Wire

ANT-GROUP

20.5.2021 09:39:09 CEST | Business Wire | Press release

Share
Ant Group Publishes its 2020 Sustainability Report: Building a Better World Together

Ant Group today released its 2020 Sustainability Report, highlighting its key activities, achievements and progress in bringing inclusive development and environmental sustainability to the world through digital technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005402/en/

In 2020, Covid-19 transformed the way people live and work. The report outlines Ant’s efforts to support Small and Micro Enterprises (SMEs) in their pandemic recovery, strengthen financial inclusion, bridge digital inequality, and promote sustainability.

“Ant Group remains committed to its mission of using technology to provide ordinary people and small businesses with more equal access to financial and daily life services,” said Ant Group’s Chairman and Chief Executive Officer Eric Jing. “As we face the challenges of today, we feel an even greater sense of responsibility and will strive to explore better solutions to serve the development of society.”

Working with its partners, Ant Group is continuing to build a future that is more inclusive, green, and sustainable, by reducing financing costs for SMEs and micro businesses and developing rural economies, investing in green technologies, and working to further protect the interests of consumers.

Key highlights from the 2020 Sustainability Report are enclosed below.

Supporting Small and Micro Enterprises

In 2020, MYbank, a leading online private commercial bank and an associate of Ant Group, served 35 million SMEs and individually-owned businesses, of which 80% were first-time borrowers of any business loans, while keeping the default rate at a low level.

MYbank’s initiatives to support SMEs’ pandemic recovery included:

  • Providing low-interest and interest-free loans to 8.5 million digital shops and small stores in Hubei Province.
  • Issuing RMB 10 billion in interest-free loan vouchers to businesses in 81 Chinese cities to support the recovery of small shops.
  • Offering a free "zero-billing period" on advance payment services to e-commerce businesses, providing advance payments of more than RMB 200 billion

Adopting and Encouraging Green Initiatives

  • In 2021, Ant announced its carbon neutrality goals and corresponding action plans, pledging to achieve carbon neutrality by 2030.
  • The company also put forward a series of intermediary goals, including a 30% reduction in absolute emissions in Scope 1 and Scope 2 by 2025 (compared with 2020), a full assessment of its supply chain emissions, and a full transition to renewable energy for its leased data center services. Ant Forest, a tree-planting mini program in the Alipay app where users earn points for making low-carbon lifestyle choices, attracted over 550 million users to plant more than 220 million real trees, helping reduce carbon emissions by more than 12 million tons as of December 2020.

Creating Opportunities for Women

  • Launched in late 2019, Ant’s A-Idol Initiative brought employment opportunities to women in less-developed areas, with women accounting for at least 60% of the employees of social enterprises incubated by the initiative.
  • As part of its "Wind Rider” project, Ant funded 40 women’s football teams in rural schools to provide women with more opportunities for education and personal development through football.
  • On July 15, 2020, Ant launched the "Cyber Mulan" program, which aims to assist 50 million women globally within five years, enhancing women's participation and competitiveness in the digital economy.

Access the full report here: https://www.antgroup.com/en/news-media/media-library?type=Sustainability%20Report

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. Ant Group strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye